Saltar al contenido
Merck

Preserved bioactivity and tunable release of a SDF1-GPVI bi-specific protein using photo-crosslinked PEGda hydrogels.

Biomaterials (2014-05-31)
Marianne K Schesny, Michael Monaghan, Andrea H Bindermann, Désirée Freund, Martina Seifert, Johannes A Eble, Sebastian Vogel, Meinrad P Gawaz, Svenja Hinderer, Katja Schenke-Layland
RESUMEN

Chemokine-induced stem cell recruitment is a promising strategy for post myocardial infarction treatment. Injection of stromal cell-derived factor 1 (SDF1) has been shown to attract bone marrow-derived progenitor cells (BMPCs) from the blood that have the potential to differentiate into cardiovascular cells, which support angiogenesis, enabling the improvement of myocardial function. SDF1-GPVI bi-specific protein contains a glycoprotein VI (GPVI)-domain that serves as an anchor for collagen type I (Col I) and III, which are exposed in the wall of injured vasculature. In this study, we generated a cytocompatible hydrogel via photo-crosslinking of poly(ethylene glycol) diacrylate that serves as a reservoir for SDF1-GPVI. Controlled and sustained release of SDF1-GPVI was demonstrated over a period of 7 days. Release features were modifiable depending on the degree of the crosslinking density. Functionality of the GPVI-domain was investigated using a GPVI-binding ELISA to Col I. Activity of the SDF1-domain was tested for its CXCR4 binding potential. Preserved functionality of SDF1-GPVI bi-specific protein after photo-crosslinking and controllable release was successfully demonstrated in vitro supporting the implementation of this drug delivery system as a powerful tool for therapeutic protein delivery in the treatment of cardiovascular ischemic disease.

MATERIALES
Referencia del producto
Marca
Descripción del producto

Sigma-Aldrich
Fosfato de 4-nitrofenilo disodium salt hexahydrate, tablet
Sigma-Aldrich
ExtrAvidin® –Alkaline Phosphatase, buffered aqueous solution